M. Ziemen

发表

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

R. Bergenstal, T. Bailey, D. Rodbard, 2017, Diabetes Care.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

R. Bergenstal, M. Riddle, H. Yki-Järvinen, 2014, Diabetes Care.

people with type 2 diabetes using basal plus mealtime insulin : the EDITION 1 12-month randomized trial , including 6-month extension

M. Riddle, H. Yki-Järvinen, G. Bolli, 2015 .

New InsulinGlargine 300 Units / mL Versus Glargine 100 Units / mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin : Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial

R. Bergenstal, M. Riddle, H. Yki-Järvinen, 2014 .

[Rotation angioplasty--a new procedure for reopening and dilating blood vessels. Experimental findings].

J. Kollath, M. Ziemen, M. Kaltenbach, 1987, Zeitschrift fur Kardiologie.

A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

M. Ziemen, A. Dressler, M. Massi Benedetti, 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Time and temperature dependent changes of ADP - and collagen-induced and "spontaneous" aggregation.

M. Ziemen, K. Breddin, W. Herrmann, 1980, Thrombosis research.

Morphologic Platelet Changes in Vitro and their Effect on Platelet Aggregation Tests

M. Ziemen, K. Breddin, A. Bauer, 1975, Thrombosis and Haemostasis.

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

H. Yki-Järvinen, M. Ziemen, H Yki-Järvinen, 2000, Diabetes care.

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes

S. Garg, P. Home, M. Ziemen, 2018, Diabetes technology & therapeutics.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

R. Bergenstal, P. Home, M. Riddle, 2015, Diabetes Care.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

R. Bergenstal, M. Riddle, G. Bolli, 2015, Diabetes, obesity and metabolism.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

P. Home, M. Riddle, G. Bolli, 2014, Diabetes Care.

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)

R. Bergenstal, P. Home, M. Riddle, 2017, Diabetes, obesity & metabolism.

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

R. Bergenstal, M. Riddle, H. Yki-Järvinen, 2015, Diabetes, obesity & metabolism.

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

M. Riddle, H. Yki-Järvinen, G. Bolli, 2015, Diabetes, obesity & metabolism.

Haemostasis during treatment with ciprofloxacin

M. Ziemen, K. Breddin, P. Shah, 2005, Infection.

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

R. Bergenstal, P. Home, M. Riddle, 2016, Diabetes technology & therapeutics.

Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. Microbiological and Clinical Study Groups.

M. Ziemen, P. Shah, V. Schäfer, 1992, The Journal of antimicrobial chemotherapy.

Enhanced platelet aggregation as a risk factor for vascular disease and its thromboembolic complications.

M. Ziemen, H. Krzywanek, K. Breddin, 1975, Acta Clinica Belgica.

Less Nocturnal Hypoglycemia and Weight Gain with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal Insulin with OADs (EDITION 2)

R. Bergenstal, M. Riddle, H. Yki-Järvinen, 2014 .

Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Results of the PARD-study.

W. Weichert, K. Uberla, M. Ziemen, 1986, International angiology : a journal of the International Union of Angiology.

Comparison of Insulin Glargine 300 U / mL and 100 U / mL in Adults With Type 1 Diabetes : Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

T. Bailey, D. Rodbard, A. Ahmann, 2017 .

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in Insulin-Naïve People with T2DM (EDITION 3)

R. Bergenstal, M. Riddle, G. Bolli, 2014 .

Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U / mL in People with Type 2

R. Bergenstal, P. Home, H. Yki-Järvinen, 2022 .

Glycemic Control and Hypoglycemia with New Insulin Glargine 300 U/mL in People with T1DM (EDITION 4)

R. Bergenstal, M. Riddle, G. Bolli, 2014 .

Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal + Mealtime Insulin (EDITION 1)

Lawrence A Leiter, P. Home, M. Riddle, 2014 .